Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Creating a joint Research Agenda for ICT Innovation in the Creative Industries across Europe (CREATE)

Framework: FP7 — Capacities
Programme: Regions of Knowledge
Destination: Transnational cooperation between regional research-driven clusters
Action type: Coordination and support actions
Countries involved: Germany,Italy,France,United Kingdom
Call:  (FP7-REGIONS-2007-1, 2007)
Start date: 2008-03-01
End date: 2010-12-31
Duration (months): 34.0
Total project cost (EUR): 1099690.0
EU funding (EUR): 984239.0
Participants: 7
Project status: CLOSED

The proposed project CReATE is based on the cooperation of highly innovative clusters in the creative industries, one of the emerging lead markets of the European knowledge economy. With the objective to bring the benefits of research to SMEs, the largest group in those clusters, the project facilitates an “open innovation” approach. It incentivates and enables a more systematic use of the innovation potential of information & communication technologies (ICT), key for developing internationally competitive products and services. To strengthen the research potential of EU regions, and to increase related investments from EU, national & regional funds, CReATE targets to position regional capabilities in the most promising international technology and market development perspectives. Prospective tools and a focus on the trans-regional dimension complement the traditional tools to lay the ground for self-sustaining economic success. Thus, CReATE promotes synergies between regional, national, EU & research policies, and facilitates intra- and trans-regional cooperation and knowledge exchange between cluster development agencies, researchers, SMEs and MNEs. To optimise outcomes, the Consortium Members have working relationships already proven successful, and can add European value with their complementary contributions. They bring in-depth knowledge of creative industries, practical cluster development and the underlying theories, and of providing strategic economic and policy intelligence in general. To optimise CReATE’s contribution to the objectives of the call we plan to 1) develop and apply a new assessment template 2) develop a joint research agenda 3) develop a toolkit, and implement training courses for interested regions, also for other clusters 4) ensure multiplying effects beyond project scope and timeframe.

Keywords: regional development,knowledge,clusters,ict,creative industries
NASAL VACCINATION AGAINST RESPIRATORY INFECTIONS IN YOUNG CHILDREN (CHILD-INNOVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Belgium,Italy,Ireland,United Kingdom,Sweden,Netherlands,Netherlands,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2012-02-29
Duration (months): 48.0
Total project cost (EUR): 7367737.97
EU funding (EUR): 5000000.0
Participants: 10
Project status: CLOSED

Respiratory infections are the most frequent cause of childhood morbidity and mortality worldwide. For many respiratory pathogens no vaccine is available, for others classical immunisations remain insufficiently effective. This project concerns the development of novel, nasal vaccines against two major respiratory pathogens, B. pertussis and Respiratory Syncytial Virus (RSV). No vaccine is yet available against RSV, and, although efficacious vaccines against pertussis are widely used, roughly 40 million cases and 200,000-400,000 pertussis-linked deaths are recorded annually, mostly in infants (<6 months) not yet sufficiently protected by the current vaccines. This proposal will yield proof of principle and provide prototypes of multivalent nasal vaccines based on attenuated B. pertussis. The concept is based on the fact that early in life, infants can mount strong anti-B. pertussis T cell responses upon natural infection in contrast to vaccination. Live attenuated B. pertussis BPZE1 has already been constructed and shown to be much more protective in infant mice after a single nasal dose than two doses of current pertussis vaccines. Immunity induced by BPZE1 will be studied in detail, and its genetic and biological stability and safety in various mouse models will be characterised. GMP lots of BPZE1 will be produced and tested for safety in a phase 1 trial in adults as a prerequisite to future trials in the target population. In parallel, human immune responses, in particular memory responses to infection and vaccination will be analysed, which will serve as a basis for immunogenic evaluations of BPZE1. Finally, we will develop BPZE1 as a vector for the presentation of heterologous RSV antigens to the respiratory mucosa. This will be tested in mouse models. A successful outcome of this project should lead to further clinical trials with BPZE1 and to the development of multivalent nasal vaccines able to protect against several respiratory pathogens simultaneously.

Keywords: pertussis,rsv,nasal vaccine,live attenuated vaccine,clinical trial
European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model (HYPERGENES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Belgium,Israel,Russian Federation,United Kingdom,France,United Kingdom,Italy,Switzerland,Italy,China,Czechia,Poland,Poland,Slovenia
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-12-31
Duration (months): 48.0
Total project cost (EUR): 14608340.8
EU funding (EUR): 10213420.0
Participants: 19
Project status: CLOSED

The project is focused on the definition of a comprehensive genetic epidemiological model of complex traits like Essential Hypertension (EH) and intermediate phenotypes of hypertension dependent/associated Target Organ Damages (TOD). To identify the common genetic variants relevant for the pathogenesis of EH and TODs, we will perform a Whole Genome Association (WGA) study of 4.000 subjects recruited from historical well-characterized European cohorts. Genotyping will be done with the Illumina Human 1M BeadChip. Well-established multi-variate techniques and innovative genomic analyses through machine learning techniques will be used for the WGA investigations. Using machine learning approach we aim at developing a disease model of EH integrating the available information on EH and TOD with relevant validated pathways and genetic/environmental information to mimic the clinician&apos;s recognition pattern of EH/TOD and their causes in an individual patient. Our statistical design is with two samples run in parallel, each with 1,000 cases and 1,000 controls, followed by a replication/joint analysis. This design is more powerful than replication alone and allows also a formal testing of the potential heterogeneity of findings compared to a single step (one large sample) design. The results represent the source to build a customized and inexpensive genetic diagnostic chip that can be validated in our existing cohorts (n=12,000 subjects). HYPERGENES is in the unique position to propose a ground-breaking project, improving the methodology of genetic epidemiology of chronic complex diseases that have a high prevalence among EU populations. Designing a comprehensive genetic epidemiological model of complex traits will also help us to translate genetic findings into improved diagnostic accuracy and new strategies for early detection, prevention and eventually personalised treatment of a complex trait. The ultimate goal will be to promote the quality of life of EU populations.

Keywords: hypertension,molecular epidemiology,genomic,postgenomic,data mining,european cohorts,innovative post genomic methods,lab-on-chip development
Plasmodium Vivax Infection in Pregnancy (PREGVAX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Sweden,Italy,Papua New Guinea,India,Italy,Brazil,Guatemala,Colombia
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2012-08-31
Duration (months): 54.0
Total project cost (EUR): 3928460.0
EU funding (EUR): 2999145.0
Participants: 9
Project status: CLOSED

Malaria in pregnancy has been recently prioritised by the EC 7th Framework Program. In response, we propose to carry out a cohort observational study in pregnant women in 5 P. vivax endemic countries, broadly representing most of the world's infections. The Indian and Papua New Guinean endemic sites are included because of their important contribution to the global burden of vivax malaria; PNG has a high prevalence of asymptomatic P. vivax infections resembling P. falciparum infection in sub-Saharan Africa, and India contributes to nearly 80% of malaria cases in Southeast Asia. In Latin America, 3 countries are selected, Guatemala, Colombia and Brazil. In Guatemala P vivax is responsible for almost all malaria cases, in Colombia and Brazil it co-exists in different proportions with falciparum. Pregnant women will be enrolled at each site during routine antenatal care visits (ANC) and followed-up at the health facility until delivery or end of pregnancy. P. vivax malaria parasitaemia will be assessed at enrolment, at every contact with the health facility and at delivery. In a sub-sample of women, peripheral blood will be taken for immunological/molecular studies, and placental samples will be collected. To assess with precision the prevalence of infection (estimated to be around 4% on average) and to obtain sufficient number of pregnant women with P vivax infection to determine the impact on birthweight, 2000 pregnant women per site will be enrolled. Due to the likely low prevalence of infection in pregnancy, the number of pregnant women with P. vivax per site will probably not be enough to assess specific impact for each site, thus a multicentric study design will be used. Immunological analysis will be performed to unveil whether there are pregnancy-specific immune responses. Phenotypic and genotypic analyses of parasites from the placenta should reveal their adhesive properties and whether the accumulation of infected erythrocytes unique parasite population.

Keywords: plasmodium vivax,malaria,pregancy,epidemiology,clnical impact,immunopathology
Modelling the spread of pandemic influenza and strategies for its containment and mitigation. (FLUMODCONT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,United Kingdom,France,Netherlands,Finland,Israel,Romania
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-06-01
End date: 2011-05-31
Duration (months): 36.0
Total project cost (EUR): 2880344.53
EU funding (EUR): 2191546.0
Participants: 11
Project status: CLOSED

The public heath threat posed by novel strains of influenza A gaining transmissibility in people and causing a human pandemic has been recognised as potentially catastrophic, especially since the emergence and global spread of the highly pathogenic avian H5N1 virus. Several mathematical models have been developed to evaluate patterns of spatio-temporal spread of infection, and the effectiveness of various containment strategies. However, these require significant improvements, elaboration, and application, in order to better inform EU-wide policy and responses. Key to the determination of the spatio-temporal patterns of pandemic influenza are data on contact patterns, such as those that are being acquired by the EU projects INFTRANS and POLYMOD. Building on these projects, we will collect detailed data on population structure, workplace sizes, and population movement; while also doing new surveys focused on identifying potential behavioral super-spreaders, and attitudes towards, and potential behavioural changes during, a pandemic. A suite of mathematical models, ranging from deterministic and stochastic differential equations to individual-based microsimulations, will be developed and integrated; taking into account all of the new data that is acquired above. The models will be validated against data on past pandemics and on the dynamics of seasonal and endemic infectious diseases. The effectiveness of control/treatment strategies, including measures to increase social distance (school and workplaces closure, travel reductions), quarantine, antiviral prophylaxis and mass or targeted vaccination, which also consider contact tracing protocols, will be evaluated through these models. An essential ingredient to the usefulness of detailed models is the possibility of updating them on the basis of new information or on the patterns of an emerging epidemic; hence a specific effort will be devoted to develop modular and efficient algorithms allowing for real-time analysis.

Keywords: pandemic influenza,mathematical models,containment strategies
EFFECT OF NATURAL VIRAL RNA SEQUENCE VARIATION ON INFLUENZA VIRUS RNA FUNCTION (RNAFLU)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Netherlands,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2010-01-31
Duration (months): 24.0
Total project cost (EUR): 1645250.0
EU funding (EUR): 1262959.0
Participants: 3
Project status: CLOSED

Influenza A virus has an amazing ability to rapidly change its properties. We believe that pathogenic properties of an influenza virus could be determined also by differences in influenza virus RNA sequence that do not affect the protein sequence of the virus genome. In other words, sequences that affect structure and/or function of the viral RNA, could themselves contribute to the pathogenic properties of the influenza A virus, as well as its ability to adopt to a new host. All RNAs in a cell are associated with proteins and RNAs are dependent on these interactions to function efficiently. Interactions of RNA with proteins depend on the RNA sequence and secondary structure. The exact RNA sequence is therefore of paramount importance since it affects secondary structure and function and utilisation efficiencies of the viral RNAs. RNA sequence has a direct effect on mRNA splicing, mRNA stability and translation. The exact sequence of the influenza virus RNA should therefore affect the replication efficiency of each virus strain. It is reasonable to speculate that RNA sequence variation itself can affect virus pathogenic properties. The immediate goal of this short, 2-year project is therefore to investigate if naturally occurring RNA sequence variations in various influenza virus isolates with different pathogenic properties affect influenza virus RNA structure and function. The long-term goal with this project, which reaches past this 2-year period applied for here, is to determine if the influenza virus RNA sequence itself, independently of effects on viral protein sequence, affects viral pathogenesis and tropism.

Keywords: influenza,spanish flu,bird flu,pathogenic,rna,secondary structure,microrna,splicing,translation,nmr
Targeting OBesity-driven Inflammation (TOBI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Germany,Italy,France,United Kingdom,United Kingdom,Austria,Austria
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 3862481.0
EU funding (EUR): 2980964.0
Participants: 10
Project status: CLOSED

The TOBI project aims to analyse mechanisms provoking adipokine-mediated crosstalk and an inflammatory drift in obese patients. It will be the remit of this project to develop novel strategies to reduce or reverse major adipokine-mediated adverse interactions in peripheral tissues and by periorganic adipose tissue, namely insulin resistance and vascular dysfunction, respectively. Special attention will be given to the study of novel lipid-derived adipokines and the identification of targets for drug development that could interfere with the obesity-associated inflammatory drift. TOBI research focuses on molecular mechanisms initiating and promoting inflammatory signalling pathways in adipocytes and adipose tissue macrophages that cause a shift to inflammatory adipokines to interfere with insulin sensitivity and vascular function. Adipocyte dysfunction by alterations in ER stress signalling and lipolysis will be analysed as probable starting points of adipocyte inflammatory alterations. Signalling pathways and transcription factors controlling expression of inflammatory adipokines and anti-inflammatory adipokines will be studied. TOBI will particularly investigate lipid-derived adipokines that have been little studied to date. Key molecules of pathophysiological relevance will be validated for their potential as targets for drug development. The TOBI consortium will mount a comprehensive collaborative program for analysing the molecular mechanisms underlying regulation of adipokine production and their function in target tissues using genetic, molecular and biochemical approaches. The consortium combines all necessary expertise to investigate the basis of the obesity-associated inflammatory drift. A TOBI toolbox will be developed that strengthen collaboration and comparability of results. In addition the consortium includes relevant partners to exploit the results by translating them into new treatment strategies for obesity-associated adipokine-mediated disorders.

Keywords: obesity,adipokines,crosstalk,inflammation,signaling,drug targets,insulin sensitivity,mutant mice,endoplasmic reticulum stress,lipases,lipid-derived mediators,lxr,vascular function
Reflecting the Positive diveRsities of European prIorities for reSearch and Measurement in end of life cAre (PRISMA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: United Kingdom,Spain,Norway,Portugal,Belgium,Netherlands,Germany,Uganda,Italy,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 1827202.0
EU funding (EUR): 1650898.0
Participants: 11
Project status: CLOSED

There is little coordination in undertaking research in end of life care. This is due to lack of agreement on what constitutes “end of life” cancer care, no information on public or clinical priorities for achieving a “good death” in a culturally diverse Europe, few appropriate measures of quality, and a lack of established best practice. “PRISMA” aims to deliver an integrated programme to coordinate research priorities and practice. The work packages will undertake actions to identify cultural differences in end of life care, establish a collaborative research agenda informed by public and clinical priorities, and draw together best practice and resources for quality measurement. The Palliative Outcome Scale (POS) is a multidimensional tool that measures the physical, psychological, spiritual and information needs of patients and families at the end of life. It has been culturally adapted in 20 EU countries and widely used by over 100 services to evaluate and improve quality of care. However, there have been no opportunities to share practice, identify shared and country-specific domains, and coordinate to improve research across Europe. By coordinating POS use, “PRISMA” will offer a model to optimise end of life care research and measurement and identify both commonalities and differences in the evaluation of quality indicators for cancer patients and their families across Europe. Incorporating wide public/clinical consultation with the coordination of POS use into this programme will advance scientifically sound practice while taking account of cultural difference and public expectations. Through integrated action, we will exchange experience, shape best practice, and plan future collaboration through identification of priorities. This will enable research to harmonise and reflect the diversity and the needs of European citizens and clinicians. Support for the POS ensures that direct impact is felt between research and daily clinical practice.

Keywords: end of life care,cancer,research,measurement,quality indicators,culture,public expectations,symptoms,nursing homes,collaboration,integration,priorities,best practice,resources
Expanding the horizons of magnetic resonance in sensitivity, imaging resolution, and availability (THE MR CHALLENGE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Physical and Analytical Chemical sciences
Countries involved: Israel
Call:  (ERC-2007-StG, 2007)
Start date: 2008-08-01
End date: 2013-07-31
Duration (months): 60.0
Total project cost (EUR): 1250000.0
EU funding (EUR): 1250000.0
Participants: 1
Project status: CLOSED

We propose to develop and implement advanced magnetic resonance detection and micro-imaging techniques that will benefit many biophysical, chemical, physical, and medical applications. Magnetic resonance (MR) is one of the most profound observation methods in science. MR includes Nuclear Magnetic Resonance (NMR) and Electron Spin Resonance (ESR). It has a variety of applications ranging from chemical structure determination to medical imaging and quantum computing. From a scientific standpoint, MR was the main focus of at least seven Nobel prizes in physics, chemistry, and medicine. From an industrial standpoint, MR is a multibillion industry focused on a range of medical (MRI) and chemical applications (MR spectrometers). Despite the fact that magnetic resonance was discovered more than 60 years ago, there is still plenty of room for new methodologies and applications. This research will confront some of the most challenging issues that this field has yet to offer, which also contain the greatest potential benefits. This is what we call “The MR Challenge”. We will focus on three key MR issues: sensitivity, image resolution, and affordability. Our first goal is to substantially improve the sensitivity of MR spectroscopy and the resolution of MR micro-imaging. We will put most of our efforts on ESR spectroscopy and on the detection of NMR information through an ESR signal (ENDOR). At ambient conditions our goal is to achieve a sensitivity of ~10^4 electron spins and a resolution of 1 micron; at low temperatures we will approach single electron spin sensitivity and image resolution as high as 10nm. In terms of affordability, our goal is to introduce a small probe that is capable of acquiring NMR spectra from samples located outside the magnet (an "ex-situ" probe). We will also design and construct a new family of hand-held 3D NMR imaging probes. The new capabilities would be applied in the field of single cell imaging and biophysics, materials science, and medicine.

Keywords: magnetic resonance esr nmr mri endor imaging sensitivity single cells single spin